Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease

David Baglietto-Vargas, Gilberto Aleph Prieto, Agenor Limon-Ruiz, Stefania Forner, Carlos J. Rodriguez-Ortiz, Kenji Ikemura, Rahasson R. Ager, Rodrigo Medeiros, Laura Trujillo-Estrada, Alessandra C. Martini, Masashi Kitazawa, Jose C. Davila, Carl W. Cotman, Antonia Gutierrez, Frank M. LaFerla

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that impairs memory and causes cognitive and psychiatric deficits. New evidences indicate that AD is conceptualized as a disease of synaptic failure, although the molecular and cellular mechanisms underlying these defects remain to be elucidated. Determining the timing and nature of the early synaptic deficits is critical for understanding the progression of the disease and for identifying effective targets for therapeutic intervention. Using single-synapse functional and morphological analyses, we find that AMPA signaling, which mediates fast glutamatergic synaptic transmission in the central nervous system (CNS), is compromised early in the disease course in an AD mouse model. The decline in AMPA signaling is associated with changes in actin cytoskeleton integrity, which alters the number and the structure of dendritic spines. AMPA dysfunction and spine alteration correlate with the presence of soluble but not insoluble Aβ and tau species. In particular, we demonstrate that these synaptic impairments can be mitigated by Aβ immunotherapy. Together, our data suggest that alterations in AMPA signaling and cytoskeletal processes occur early in AD. Most important, these deficits are prevented by Aβ immunotherapy, suggesting that existing therapies, if administered earlier, could confer functional benefits.

Original languageEnglish (US)
Article numbere12791
JournalAging Cell
Volume17
Issue number4
DOIs
StatePublished - Aug 1 2018
Externally publishedYes

Fingerprint

alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Alzheimer Disease
Immunotherapy
Dendritic Spines
Actin Cytoskeleton
Synaptic Transmission
Neurodegenerative Diseases
Synapses
Psychiatry
Disease Progression
Spine
Central Nervous System
Therapeutics

Keywords

  • actin cytoskeleton
  • Alzheimer's disease
  • AMPA receptor
  • immunotherapy
  • synaptic impairment

ASJC Scopus subject areas

  • Aging
  • Cell Biology

Cite this

Baglietto-Vargas, D., Prieto, G. A., Limon-Ruiz, A., Forner, S., Rodriguez-Ortiz, C. J., Ikemura, K., ... LaFerla, F. M. (2018). Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. Aging Cell, 17(4), [e12791]. https://doi.org/10.1111/acel.12791

Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. / Baglietto-Vargas, David; Prieto, Gilberto Aleph; Limon-Ruiz, Agenor; Forner, Stefania; Rodriguez-Ortiz, Carlos J.; Ikemura, Kenji; Ager, Rahasson R.; Medeiros, Rodrigo; Trujillo-Estrada, Laura; Martini, Alessandra C.; Kitazawa, Masashi; Davila, Jose C.; Cotman, Carl W.; Gutierrez, Antonia; LaFerla, Frank M.

In: Aging Cell, Vol. 17, No. 4, e12791, 01.08.2018.

Research output: Contribution to journalArticle

Baglietto-Vargas, D, Prieto, GA, Limon-Ruiz, A, Forner, S, Rodriguez-Ortiz, CJ, Ikemura, K, Ager, RR, Medeiros, R, Trujillo-Estrada, L, Martini, AC, Kitazawa, M, Davila, JC, Cotman, CW, Gutierrez, A & LaFerla, FM 2018, 'Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease', Aging Cell, vol. 17, no. 4, e12791. https://doi.org/10.1111/acel.12791
Baglietto-Vargas, David ; Prieto, Gilberto Aleph ; Limon-Ruiz, Agenor ; Forner, Stefania ; Rodriguez-Ortiz, Carlos J. ; Ikemura, Kenji ; Ager, Rahasson R. ; Medeiros, Rodrigo ; Trujillo-Estrada, Laura ; Martini, Alessandra C. ; Kitazawa, Masashi ; Davila, Jose C. ; Cotman, Carl W. ; Gutierrez, Antonia ; LaFerla, Frank M. / Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease. In: Aging Cell. 2018 ; Vol. 17, No. 4.
@article{88ef896a1e874268ae31c88ca1577202,
title = "Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a devastating neurodegenerative disorder that impairs memory and causes cognitive and psychiatric deficits. New evidences indicate that AD is conceptualized as a disease of synaptic failure, although the molecular and cellular mechanisms underlying these defects remain to be elucidated. Determining the timing and nature of the early synaptic deficits is critical for understanding the progression of the disease and for identifying effective targets for therapeutic intervention. Using single-synapse functional and morphological analyses, we find that AMPA signaling, which mediates fast glutamatergic synaptic transmission in the central nervous system (CNS), is compromised early in the disease course in an AD mouse model. The decline in AMPA signaling is associated with changes in actin cytoskeleton integrity, which alters the number and the structure of dendritic spines. AMPA dysfunction and spine alteration correlate with the presence of soluble but not insoluble Aβ and tau species. In particular, we demonstrate that these synaptic impairments can be mitigated by Aβ immunotherapy. Together, our data suggest that alterations in AMPA signaling and cytoskeletal processes occur early in AD. Most important, these deficits are prevented by Aβ immunotherapy, suggesting that existing therapies, if administered earlier, could confer functional benefits.",
keywords = "actin cytoskeleton, Alzheimer's disease, AMPA receptor, Aβ, immunotherapy, synaptic impairment",
author = "David Baglietto-Vargas and Prieto, {Gilberto Aleph} and Agenor Limon-Ruiz and Stefania Forner and Rodriguez-Ortiz, {Carlos J.} and Kenji Ikemura and Ager, {Rahasson R.} and Rodrigo Medeiros and Laura Trujillo-Estrada and Martini, {Alessandra C.} and Masashi Kitazawa and Davila, {Jose C.} and Cotman, {Carl W.} and Antonia Gutierrez and LaFerla, {Frank M.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1111/acel.12791",
language = "English (US)",
volume = "17",
journal = "Aging Cell",
issn = "1474-9718",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease

AU - Baglietto-Vargas, David

AU - Prieto, Gilberto Aleph

AU - Limon-Ruiz, Agenor

AU - Forner, Stefania

AU - Rodriguez-Ortiz, Carlos J.

AU - Ikemura, Kenji

AU - Ager, Rahasson R.

AU - Medeiros, Rodrigo

AU - Trujillo-Estrada, Laura

AU - Martini, Alessandra C.

AU - Kitazawa, Masashi

AU - Davila, Jose C.

AU - Cotman, Carl W.

AU - Gutierrez, Antonia

AU - LaFerla, Frank M.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Alzheimer's disease (AD) is a devastating neurodegenerative disorder that impairs memory and causes cognitive and psychiatric deficits. New evidences indicate that AD is conceptualized as a disease of synaptic failure, although the molecular and cellular mechanisms underlying these defects remain to be elucidated. Determining the timing and nature of the early synaptic deficits is critical for understanding the progression of the disease and for identifying effective targets for therapeutic intervention. Using single-synapse functional and morphological analyses, we find that AMPA signaling, which mediates fast glutamatergic synaptic transmission in the central nervous system (CNS), is compromised early in the disease course in an AD mouse model. The decline in AMPA signaling is associated with changes in actin cytoskeleton integrity, which alters the number and the structure of dendritic spines. AMPA dysfunction and spine alteration correlate with the presence of soluble but not insoluble Aβ and tau species. In particular, we demonstrate that these synaptic impairments can be mitigated by Aβ immunotherapy. Together, our data suggest that alterations in AMPA signaling and cytoskeletal processes occur early in AD. Most important, these deficits are prevented by Aβ immunotherapy, suggesting that existing therapies, if administered earlier, could confer functional benefits.

AB - Alzheimer's disease (AD) is a devastating neurodegenerative disorder that impairs memory and causes cognitive and psychiatric deficits. New evidences indicate that AD is conceptualized as a disease of synaptic failure, although the molecular and cellular mechanisms underlying these defects remain to be elucidated. Determining the timing and nature of the early synaptic deficits is critical for understanding the progression of the disease and for identifying effective targets for therapeutic intervention. Using single-synapse functional and morphological analyses, we find that AMPA signaling, which mediates fast glutamatergic synaptic transmission in the central nervous system (CNS), is compromised early in the disease course in an AD mouse model. The decline in AMPA signaling is associated with changes in actin cytoskeleton integrity, which alters the number and the structure of dendritic spines. AMPA dysfunction and spine alteration correlate with the presence of soluble but not insoluble Aβ and tau species. In particular, we demonstrate that these synaptic impairments can be mitigated by Aβ immunotherapy. Together, our data suggest that alterations in AMPA signaling and cytoskeletal processes occur early in AD. Most important, these deficits are prevented by Aβ immunotherapy, suggesting that existing therapies, if administered earlier, could confer functional benefits.

KW - actin cytoskeleton

KW - Alzheimer's disease

KW - AMPA receptor

KW - Aβ

KW - immunotherapy

KW - synaptic impairment

UR - http://www.scopus.com/inward/record.url?scp=85050258896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050258896&partnerID=8YFLogxK

U2 - 10.1111/acel.12791

DO - 10.1111/acel.12791

M3 - Article

C2 - 29877034

AN - SCOPUS:85050258896

VL - 17

JO - Aging Cell

JF - Aging Cell

SN - 1474-9718

IS - 4

M1 - e12791

ER -